Brown tumours are the end stage of primary or secondary hyperparathyroidism. Clinically, brown tumours most often manifest as slowly growing, painful masses. These tumours can behave aggressively and be destructive. We report a patient with high accumulation of fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in brown tumours as the potential cause of false-positive results in the evaluation of a patient for malignant primary tumour or metastases.
In view of the lesion inferior to the left lobe of the thyroid, the patient was subsequently evaluated for hyperparathyroidism.
His serum calcium level was 3.21 mmol/l (normal range: 2.10 -2.55 mmol/l). His alkaline phosphatase concentration was 241 IU/l (normal range: 40 -150 IU/l), and his parathyroid hormone level was 682 pg/ml (normal range: 12 -72 pg/ml).
Tc-99m methoxy isobutyl isonitrile (MIBI) parathyroid scintigraphy revealed a parathyroid adenoma inferior to the left thyroid lobe ( Fig. 3 ) and ultrasonography showed a 6 × 9 mm nodule of the inferior left parathyroid gland. Parathyroidectomy was undertaken and histopathological examination revealed the presence of a parathyroid adenoma. Postoperatively, plasma parathyroid hormone and calcium levels normalised. Based on these results, the osteolytic FDG avid bone lesions were classified as multiple brown tumours caused by primary hyperparathyroidism. The lesion localises in areas of intense bone resorption, and the bone defect becomes filled with fibroblastic tissue that can deform the bone and simulate a neoplastic process. 5 These tumours have a brown or yellow hue. 6 Skeletal changes may represent the first manifestations of hyperparathyroidism, with a loss of cortical bone and an increase in trabecular bone. Bone pain and arthralgia are the most common symptoms, such as in our case.
Brown tumours exhibit no pathognomonic histological changes. Findings may include a dense fibroblastic stroma, areas of cystic degeneration, osteoid, microfractures, haemorrhage, macrophages with hemosiderin, and multinucleated osteoclastic giant cells. Similar changes may occur in fibrous dysplasia, true giant-cell tumours, and reparative granulomas. 5 Histologically, brown tumours may be indistinguishable from giant-cell tumours of the bone, and correlation with clinical findings and imaging studies is essential in making the correct diagnosis.
The presence of giant cells has been suggested as partially contributing to the high uptake of FDG in benign bone lesions such as brown tumours. [7] [8] [9] Another supporting mechanism for the elevated FDG uptake is that macrophages play a central role in the host response to injury, and their energy is predominantly supplied by means of intracellular glucose metabolism. 10, 11 In conclusion, PET-CT readers should be aware of the high accumulation of FDG in brown tumours as a potential cause of false-positive results in the evaluation of a patient for malignant primary tumour or metastases. 
